ARDX
Ardelyx, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +5.9% ·
share flow -2.7% ·
net new positions +5.6%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 96 | 0 | 123.12M | $629.22M | +7 | −8 |
| Q1 2026 | 100 | +3 | 138.17M | $826.25M | +6 | −3 |
| Q4 2025 | 95 | +1 | 146.57M | $854.46M | +1 | — |
| Q3 2025 | 18 | +1 | 90.83M | $500.46M | +1 | — |
| Q2 2025 | 14 | -2 | 85.87M | $336.62M | — | −2 |
| Q1 2025 | 13 | +1 | 41.26M | $202.59M | +2 | −1 |
| Q4 2024 | 12 | +2 | 28.08M | $142.38M | +3 | −1 |
| Q3 2024 | 9 | 0 | 14.54M | $100.22M | — | — |
| Q2 2024 | 9 | — | 13.39M | $99.20M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 20.82M | +0.4% | $114.74M | 0.0% | ▲ Add | 2 | SEC ↗ ×13 |
| 2 | The Vanguard Group ✦ (passive) | 18.37M | +14.6% | $101.21M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 9.72M | -1.2% | $53.55M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Marshall Wace ✦ | 8.94M | -20.5% | $49.28M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 7.64M | -34.5% | $42.11M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 5.76M | +1.6% | $31.72M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | D. E. Shaw & Co. ✦ | 3.31M | +34.8% | $18.25M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Morgan Stanley ✦ | 2.89M | — | $15.90M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 9 | Goldman Sachs Group ✦ | 2.58M | — | $14.24M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Two Sigma Investments ✦ | 2.49M | +23.2% | $13.72M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 2.14M | -7.3% | $11.81M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 12 | JPMorgan Chase ✦ | 2.01M | — | $11.06M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 13 | Renaissance Technologies ✦ | 1.69M | +29.9% | $9.31M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 1.53M | -30.9% | $8.42M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 15 | Arrowstreet Capital ✦ | 579.02K | New | $3.19M | 0.0% | New | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 227.32K | +9.7% | $1.25M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | Wellington Management ✦ | 102.57K | +5.1% | $565,139 | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 18 | Fidelity (FMR) ✦ | 21.39K | -64.1% | $117,864 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $3.19M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 235 holders, 168.96M shares, $997.54M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 15.01K sh · $57,888
Officer, Director · 15.98K sh · $61,618
Officer, Director · 8.41K sh · $32,440
Officer, Director · 19.18K sh · $73,968
Officer · 1.56K sh · $6,009
Officer · 3.49K sh · $13,445
Officer · 3.09K sh · $11,914
Officer · 2.43K sh · $9,372
Officer · 1.73K sh · $6,688
Officer · 3.10K sh · $11,972
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology